• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Aug 20, 2022
Deals

How Ultragenyx delivered win for biotech venture philanthropy via GeneTx deal

Rare disease company invested in a spinout of a non-profit that was making science decisions, not just writing checks
BioCentury | Aug 31, 2021
Regulation

New surrogate endpoints need resolution of ‘reasonably likely’ 

Regulatory clarity, consistency, key to taking accelerated approval outside of cancer
BioCentury | Aug 30, 2021
Regulation

The promise and problems of expediting drug approvals

Overview of status of expedited approval pathways sets stage for BioCentury’s 29th Back to School
BioCentury | Dec 8, 2017
Product Development

Making of Mepsevii

Why Ultragenyx developed Mepsevii for ultra-rare indication MPS VII
BioCentury | Mar 28, 2016
Strategy

Canbridge can-can

Why Aveo's AV-203 is leading Canbridge to venture outside Asia
BioCentury | Dec 8, 2014
Strategy

BioMarin bulks up

Why BioMarin buying Prosensa despite drisapersen Phase III miss in DMD
BioCentury | Oct 16, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

BioCentury | Sep 18, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

BioCentury | Jun 16, 2014
Regulation

Signal crossing

Caregivers want more real-world, caregiver-reported outcomes in inborn errors
BioCentury | Mar 31, 2014
Regulation

Viral crossroads

Hardy case shows flaws in compassionate use system, provides catalyst for change
Items per page:
1 - 10 of 174